Sun Pharma receives nod to sell Cymbalta copy
Sun Pharma can sell the capsules for 180 days without competition from rival generic drug makers
Mumbai: Sun Pharmaceutical Industries Ltd, India’s most valuable drug maker, on Thursday said it has received approval from the US Food and Drug Administration (FDA) to sell a copy of drug maker Eli Lilly and Co.’s Cymbalta capsules that is used for the treatment of depression and anxiety disorders.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more